Bristol-Myers Squibb (NYSE:BMY) said today that it landed an exclusive licensing agreement for PsiOxus Therapeutics‘ ‘armed’ oncolytic virus, NG-348, for the treatment of solid tumors. According to the agreement, Bristol-Myers will pay PsiOxus $50 million upfront and will assume responsibility for global clinical development and commercialization. PsiOxus will be eligible for $886 million in development, regulatory and […]
Bristol-Myers Squibb Co.
Bristol-Myers Squibb, Enterome ink immuno-oncology collab
Bristol-Myers Squibb (NYSE:BMY) said today that it inked a collaboration agreement with Enterome to discover and develop microbiome-derived biomarkers and drug targets as potential companion diagnostics and therapeutics for cancer. According to the agreement, Bristol-Myers Squibb will be given exclusive rights to intellectual property and therapies that result from the collaboration. Enterome will get an […]
Bristol-Myers Squibb launches Orencia ClickJect drug-device combo for rheumatoid arthritis
Bristol-Myers Squibb said today it launched the Orencia ClickJect autoinjector designed for the self-administration of Orencia to treat moderate to severe rheumatoid arthritis. The Orencia ClickJect is designed to deliver 125 mg of subcutaneous Orencia through a push button operation with injection confirmation to reduce the possibility of user errors, the company said. “Today’s launch […]
Lantheus pays $6.2M to settle tax evasion row
Lantheus Medical Imaging signed a settlement with the office of New York Attorney General Eric Schneiderman, agreeing to pay $6.2 million to settle allegations that the company and former parent Bristol-Myers Squibb schemed to avoid paying sales taxes.